Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder

  title={Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder},
  author={Richard A. Hansen and Gerald Gartlehner and Kathleen N. Lohr and Bradley N. Gaynes and Timothy S. Carey},
  journal={Annals of Internal Medicine},
Context The relative benefits and harms of newer, second-generation antidepressants are sometimes confusing. Contribution In this review of 46 head-to-head randomized trials, the authors generally found no major differences in the numbers of adults with major depression who responded to second-generation antidepressants, such as selective serotonin reuptake inhibitors, bupropion, duloxetine, mirtazapine, and venlafaxine. The overall incidence of adverse events appeared similar across drugs… 
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
This is the first meta-analysis of second-generation antidepressants to assess quantitatively all possible comparisons among drugs in this class and to determine whether efficacy, effectiveness, and harms differed among subgroups of patients on the basis of age, sex, race or ethnicity, or comorbid conditions.
Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder
Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine
Introduction: As a leading cause of disability, major depressive disorder (MDD) is characterized by reduced quality of life and altered functioning. Current pharmaceutical treatment options are
Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
Vilazodone, which has been described as the first-of-class SPARI medication, may potentially have benefits for subgroups of patients, particularly those depressed individuals with coexisting anxiety symptoms or anxiety disorders, but convincing evidence for these benefits has as yet not been published.
Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine
Fuvoxamine has a proven efficacy and safety profile in treating elderly patients with depression and its σ1-receptor binding profile may account for the observed high level of efficacy in psychotic depression and may explain the benefit of fluvoxamine in treating depression comorbid with anxiety/stress.
Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis
A systematic review of randomized controlled trials to synthesize the best available evidence on the efficacy of fluvoxamine for adult patients suffering from major depression in comparison with other active antidepressive agents found no large differences between fluv oxamine and any other antidepressants.
Faster Onset of Antidepressant Effects of Citalopram Compared With Sertraline in Drug-Naïve First-Episode Major Depressive Disorder in a Chinese Population: A 6-Week Double-Blind, Randomized Comparative Study
Citalopram exhibited a significantly faster onset than sertraline during the early weeks of treatment and tended to have a better efficacy in overall treatment, although the statistic was not significant.
Choosing a Second-Generation Antidepressant using Demographic Characteristics and Clinical Symptoms of Depression
This study found that when treating sadness, paroxetine and venlafaxine should be avoided in depression with low moods, fluoxetines should be avoiding in depressed with high anxiety, and sertraline should been avoided in Depression with high levels of fatigue.
Efficacy and Tolerability of Milnacipran in the Treatment of Major Depression in Comparison with Other Antidepressants
There is some evidence in favour of milnacipran over TCAs in terms of premature withdrawal due to adverse events and the rates of patients experiencing adverse events, and the overall effectiveness and tolerability does not seem to differ in the acute phase of treatment for major depression.
Duloxetine in the treatment of major psychiatric and neuropathic disorders
Duloxetine is an interesting novel treatment option in the management of major depression and has shown efficacy in a broad range of diseases, and may provide additional benefit to current therapeutic options in the treatment of psychiatric, internal, as well as urological disorders such as spinal dysfunctions.


Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis
Taking the similar efficacy of second-generation antidepressant into account, the findings suggest that clinicians can focus on other practically or clinically relevant considerations such as costs, differences in side-effect profiles, onset of action or aspects of health-related quality of life to tailor a treatment to an individual patient's needs.
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
It is suggested that men and women have comparable responses to SSRIs and venlafaxine across various age groups and patients exhibited a more rapid onset and a greater likelihood of remission with venl Lafaxine therapy than with SSRI therapy regardless of age or gender.
A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.
Data indicate that both drugs are effective antidepressants for the treatment of depressed elderly outpatients and differences in cognitive performance effects deserve further investigation.
A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2
The goal was to summarize data on the efficacy of newer antidepressants and herbal treatments compared with placebo, older antidepressants, and each other for a broad spectrum of depressive disorders.
Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia
Improvement in overall depression and in associated insomnia was achieved by most patients regardless of baseline insomnia, and data show no significant differences in acute treatment efficacy and tolerability across fluoxetine, sertraline, and paroxettine in major depressive disorder patients.
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Because of its favorable side effect profile, bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly.
Meta-analytical studies on new antidepressants.
  • I. Anderson
  • Psychology, Medicine
    British medical bulletin
  • 2001
A systematic search found 108 meta-analyses of the use of antidepressants in depressive disorders of uneven quality and confidence, which limits the confidence in many of the results.
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxettine-treated patients compared with placebo- treated patients.